Search for: "Grant v. Bristol-Myers Squibb"
Results 81 - 100
of 157
Sorted by Relevance
|
Sort by Date
2 Jun 2010, 3:15 am
” Bristol-Myers Squibb Co., 326 F.3d at 1241; see Molins PLC, 48 F.3d at 1182 (“We recognize that [the withheld references] were cited eventually to the PTO and that the examiner . . . passed the reexamination application to issue thereafter. [read post]
11 Nov 2009, 4:02 am
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: EU: Generics producers: Criminal sanctions can stop counterfeit drugs (IP Watch) Prandin (Repaglinide) - US: Federal Circuit grants stay of preliminary relief pending full appellate review: Novo Nordisk v Caraco (Patently-O) General Eduardo Pisani of Bristol-Myers Squibb is the new IFPMA Director General (IP… [read post]
29 Nov 2013, 3:43 am
Bristol-Myers Squibb Co., No. 13-1405, 2013 U.S. [read post]
1 Jul 2009, 7:14 am
(Patent Docs) Products Avapro (Irbesartan) – Spain: Fourth Commercial Court of Barcelona rejects preliminary injunction petition by Sanofi-Aventis and Bristol-Myers Squibb for alleged patent infringement (International Law Office) Cozaar/Hyzaar (Losartan/Hydrochlorothiazide and Losartan) –US: Teva sues FDA over generic Cozaar and Hyzaar 180-day exclusivity forfeiture and patent delisting rule (The FDA Law Blog) Eloxatin (Oxaliplatin) – US:… [read post]
30 Aug 2011, 2:00 am
US 6,475,521entitled BIPHASIC CONTROLLED RELEASE DELIVERY SYSTEM FOR HIGH SOLUBILITY PHARMACEUTICALS AND METHOD and owned by Bristol-Myers Squibb Co. [read post]
30 Aug 2011, 2:00 am
US 6,475,521entitled BIPHASIC CONTROLLED RELEASE DELIVERY SYSTEM FOR HIGH SOLUBILITY PHARMACEUTICALS AND METHOD and owned by Bristol-Myers Squibb Co. [read post]
8 Jul 2013, 8:10 am
Bristol-Myers Squibb Co., 2013 U.S. [read post]
24 May 2012, 4:23 am
Bristol-Myers Squibb Co., 2011 WL 2784101, at *3 (D.N.J. 2011), the Court did not hold that the warning label was enough to give notice. [read post]
2 Jun 2011, 12:46 pm
Squibb & Sons, Inc. v. [read post]
10 Jun 2009, 10:00 pm
Bristol-Myers Squibb, 1998 WL 812318, at 30 (M.D. [read post]
7 Jul 2021, 11:44 pm
The Patentees filed two PTE applications, each of which was based on different goods on the ARTG: Brand Name OPDIVO® KEYTRUDA® Active ingredient nivolumab pembrolizumab Australian sponsor Bristol-Myers Squibb Australia Pty Ltd Merck Sharp & Dohme (Australia) Pty Ltd Relationship between sponsor and patentees Related to one of the patentees Not related to either patentee Date goods containing the drug were first included on ARTG 11 January 2016 16 April 2015… [read post]
31 Oct 2008, 11:53 am
You can separately subscribe to the Pharma & Biotech edition of the IP Think Tank Global Week in Review by subscribing by email, or selecting ‘all posts’ or ‘Pharma, Biotech & Chem’ for the RSS option at the Subscribe page: [duncanbucknell.com] Highlights this week included: Oxytrol (Oxybutynin) - US: Watson files patent infringement lawsuit against Barr over application to market generic Oxytrol; Barr challenges Oxytrol patent… [read post]
12 May 2022, 6:45 am
Paul Reed Smith Guitars, LP, 423 F.3d 539 (6th Cir. 2005). [3] Bristol-Myers Squibb Co. v. [read post]
4 Nov 2010, 6:14 am
”); Bristol-Myers Squibb Co. v. [read post]
4 Feb 2013, 2:07 pm
Bristol—Myers Squibb Co., No. 07-1098 (FLW), 2013 U.S. [read post]
18 Mar 2011, 10:04 am
Bristol-Myers Squibb, 97 F. [read post]
7 Nov 2022, 9:01 pm
Supreme Court, which granted certiorari. [read post]
3 Mar 2010, 5:05 am
‘The solution lies in resources’ says FDA Commissioner Hamburg (FDA Law Blog) Products Actoplus MET (Pioglitazone) – US: Takeda files patent infringement suit against Aurobindo following Para IV certification as part of ANDA to manufacture generic Actoplus MET (Patent Docs) Advair diskus (Fluticasone, Salmeterol) – US: PTO denies PTE for Advair diskus patent; Office again clarifies that PTEs are not availabile for ‘synergistic combinations’ containing… [read post]
3 Mar 2010, 5:05 am
‘The solution lies in resources’ says FDA Commissioner Hamburg (FDA Law Blog) Products Actoplus MET (Pioglitazone) – US: Takeda files patent infringement suit against Aurobindo following Para IV certification as part of ANDA to manufacture generic Actoplus MET (Patent Docs) Advair diskus (Fluticasone, Salmeterol) – US: PTO denies PTE for Advair diskus patent; Office again clarifies that PTEs are not availabile for ‘synergistic combinations’ containing… [read post]
9 Dec 2009, 3:59 pm
(Patent Docs) (SmartBrief) (GenericsWeb) OxyContin (Oxycodone) – US: Ranbaxy admits infringement in OxyContin suit – District Court S D New York approves consent judgment between Ranbaxy and Purdue Pharma (Patent Docs) Reyataz (Atazanavir) – US: Complaint filed in Delaware: Infringement of US patent following a Paragraph IV challenge: Bristol-Myers Squibb Co. et al. v. [read post]
